MAPREG is a privately held company.
Shareholders include founders, management, business angels/family offices and institutional investors.

To date MAPREG has raised closed to €20 millions equity with 100% leverage effect to research supports among which OSEO/BPI, US Army, Eureka/European Grant, CIR.

MAPREG is currently raising a bridge for launching Phase 2b/3 in TRD with further partners.

Grants

BPI (the French public bank for innovation): 2 successive financial supports to help MAPREG complete the preclinical package of its lead compound.
US ARMY :  2 successive competitive grants to wrap a preclinical case in Traumatic Brain Injuries
EUREKA/EUROSTARS : competitive grant to generate the preclinical proof of concept datapackage in Major Depressive Disorder.